These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 35018245)
21. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536 [TBL] [Abstract][Full Text] [Related]
22. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus. Lyu T; Yao H; Wang J; Song L; Tong X; Zou Y Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101819. PubMed ID: 34619365 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Tang Q; Huang W; Liang J; Xue J Front Oncol; 2021; 11():646410. PubMed ID: 34307128 [TBL] [Abstract][Full Text] [Related]
25. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. Fan W; Zhu B; Zheng X; Yue S; Lu M; Fan H; Qiao L; Li F; Yuan G; Wu Y; Zou X; Wang H; Xue M; Li J J Cancer Res Clin Oncol; 2023 May; 149(5):1873-1882. PubMed ID: 35788728 [TBL] [Abstract][Full Text] [Related]
26. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889 [TBL] [Abstract][Full Text] [Related]
27. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655 [TBL] [Abstract][Full Text] [Related]
28. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002 [TBL] [Abstract][Full Text] [Related]
30. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE. Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156 [TBL] [Abstract][Full Text] [Related]
31. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma. Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062 [TBL] [Abstract][Full Text] [Related]
32. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial. Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448 [TBL] [Abstract][Full Text] [Related]
33. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Zou X; Xu Q; You R; Yin G Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575 [TBL] [Abstract][Full Text] [Related]
35. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963 [TBL] [Abstract][Full Text] [Related]
36. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. Chen J; Lai L; Luo J; Wang H; Li M; Huang M BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104 [TBL] [Abstract][Full Text] [Related]